Floatz logo

Ibrutinib

Asymptomatic COVID-19 Infection Laboratory-Confirmed

Academic and Community Cancer Research UnitedSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Asymptomatic COVID-19 Infection Laboratory-Confirmed cohort.

Asset / SponsorPhaseRating
RECOMBINANT ADENOVIRUS TYPE 5 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN (CANSINO BIOLOGICS)
Seventh Medical Center of PLA General Hospital
Phase 3BBB
Genotropin
ClinAmygate
Phase 4BB
cc-220
Nguyen Thi Trieu, MD
Phase 4BB
Tocilizumab
National Cancer Institute (NCI)
Phase 3BB
Oxygen
Jay C. Buckey Jr.
Phase 4BB

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →